“…This issue is partially circumvented with the use of more rare Ad serotypes with lower baseline vectorspecific neutralizing antibody titers (1,6). Second, since the hepatic tropism of Ad5 markedly differs from that of alternativeserotype Ads (7,46,47), these different viral vectors may trigger specific innate pathways that may affect the phenotype of adaptive immune responses (48)(49)(50)(51)(52)(53). Moreover, Ad5 uses the CAR receptor, which is highly expressed on epithelial tight junctions, liver, and red blood cells, among other cell types (54), whereas Ad26, Ad35, and Ad48 utilize the complement receptor CD46 (1,7,47,55,56), which is ubiquitously expressed on all nucleated cells (55,57).…”